To amend title XVIII of the Social Security Act to extend eligibility for certain payment increases for biosimilar biological products under the Medicare program.
Latest action (14 Nov 2023): Introduced
What this bill does
H.R. 6400, introduced in the House of Representatives, proposes to extend eligibility for specific payment increases for biosimilar biological products within the Medicare program. Currently, these increases are set to expire in 2027. This bill would amend the Social Security Act to extend this eligibility until 2032.
The bill directly affects Medicare beneficiaries who use biosimilar biological products. It also impacts manufacturers of these products and the Medicare program's payment structure for them. The proposed change would extend a financial incentive related to biosimilar product adoption under Medicare for an additional five years.
This bill was introduced on November 14, 2023, and referred to the House Committees on Energy and Commerce, and Ways and Means. As of its introduction, it has not received a vote and is in the early stages of the legislative process. If it moves forward, it would need to be considered by these committees before potentially being brought to the House floor for a vote.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
This bill was introduced on November 14, 2023, in a previous session of Congress, but it did not receive a vote.
Common questions
- What does H.R. 6400 do?
- H.R. 6400, introduced in the House of Representatives, proposes to extend eligibility for specific payment increases for biosimilar biological products within the Medicare program. Currently, these increases are set to expire in 2027. This bill would amend the Social Security Act to extend this eligibility until 2032. The bill directly affects Medicare beneficiaries who use biosimilar biological products. It also impacts manufacturers of these products and the Medicare program's payment structure for them. The proposed change would extend a financial incentive related to biosimilar product adoption under Medicare for an additional five years. This bill was introduced on November 14, 2023, and referred to the House Committees on Energy and Commerce, and Ways and Means. As of its introduction, it has not received a vote and is in the early stages of the legislative process. If it moves forward, it would need to be considered by these committees before potentially being brought to the House floor for a vote.
- Has H.R. 6400 become law?
- Not yet. As of 14 Nov 2023, H.R. 6400 is introduced.
- Who sponsored H.R. 6400?
- H.R. 6400 was sponsored by Rep. Tony Cárdenas [D-CA29, 2013-2024] (Democrat-CA), with 0 cosponsors.
- What's the latest action on H.R. 6400?
- Introduced (14 Nov 2023).
Related bills in Health
Choices for Increased Mobility Act of 2026
A resolution supporting the designation of October 2026 as “Substance Use & Misuse Prevention Month” to raise awareness of substance use and misuse in the United States.
Kay Hagan Tick Reauthorization Act
Making America's Food Safer Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.